Skip to main content

Advertisement

SpringerLink
Log in

Conventional and Novel Drug Therapeutics to Relief Myocardial Ischemia

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Effective management of stable angina usually includes drug therapy. There are several agents that are considered vasculoprotective such as aspirin, angiotensin converting enzyme inhibitors and statins. Conventional anti ischemic therapy includes nitrates, beta-blockers and calcium-channel blockers. In recent years, several other drugs with novel anti ischemic mechanisms have become available including ranolazine, ivabradine, nicorandil and many others. This article reviews drugs that alleviate the symptoms of chronic angina with emphasis on several novel pharmacological agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ben-Dor I, Battler A. Treatment of stable angina. Heart. 2007;93:868–74.

    Article  CAS  PubMed  Google Scholar 

  2. Chaitman BR, Sano J. Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease. Clin Cardiol. 2007;30:I25–30.

    Article  PubMed  Google Scholar 

  3. Savonitto S, Ardissino D. Selection of drug therapy in stable angina pectoris. Cardiovasc Drugs Ther. 1998;12:197–210.

    Article  CAS  PubMed  Google Scholar 

  4. Thadani U. Treatment of stable angina. Curr Opin Cardiol. 1999;14:349–58.

    Article  CAS  PubMed  Google Scholar 

  5. Fraker Jr TD, Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation. 2007;116:2762–72.

    Article  PubMed  Google Scholar 

  6. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341–81.

    Article  PubMed  Google Scholar 

  7. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281:1927–36.

    Article  CAS  PubMed  Google Scholar 

  8. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326–31.

    CAS  PubMed  Google Scholar 

  9. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281:1927–36.

    Article  CAS  PubMed  Google Scholar 

  10. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998;338:520–31.

    Article  CAS  PubMed  Google Scholar 

  11. Pepine CJ, Lopez LM, Bell DM, et al. Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: results of the second transdermal intermittent dosing evaluation study (TIDES-II). J Am Coll Cardiol. 1997;30:955–61.

    Article  CAS  PubMed  Google Scholar 

  12. Siddiqui MA, Keam SJ. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs. 2006;66:693–710.

    Article  CAS  PubMed  Google Scholar 

  13. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904–10.

    Article  CAS  PubMed  Google Scholar 

  14. Rousseau MF, Pouleur H, Cocco G, et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95:311–6.

    Article  CAS  PubMed  Google Scholar 

  15. Chaitman BR, Pepine CJ, Parker JO, et al. For the Combination Assessment of Ranolazine In Stable Angina (CARISA) investigators: effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA. 2004;291:309–16.

    Article  CAS  PubMed  Google Scholar 

  16. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN)–TIMI 36 trial. Am Heart J. 2006;151:1186e1–9.

    Article  Google Scholar 

  17. Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48:566–75.

    Article  CAS  PubMed  Google Scholar 

  18. Chisholm JW, Goldfine AB, Dhalla AK, et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diab Care. 2010;33:1163–8.

    Article  CAS  Google Scholar 

  19. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27:42–8.

    Article  CAS  PubMed  Google Scholar 

  20. Jerling M, Huan BL, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45:422–33.

    Article  CAS  PubMed  Google Scholar 

  21. Simpson D, Wellington K. Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients. Drugs. 2004;64:1941–55.

    Article  CAS  PubMed  Google Scholar 

  22. Abete P, Cacciatore F, Testa G, et al. Clinical application of ischemic preconditioning in the elderly. Dose Response. 2009;8:34–40.

    Article  PubMed  Google Scholar 

  23. Chen JW, Lee WL, Hsu NW, et al. Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina. Am J Cardiol. 1997;80:32–8.

    Article  CAS  PubMed  Google Scholar 

  24. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomised trial. Lancet. 2002;359:1269–75.

    Article  Google Scholar 

  25. Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817–23.

    Article  PubMed  Google Scholar 

  26. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529–36.

    Article  CAS  PubMed  Google Scholar 

  27. Borer JS. Therapeutic effects of I(f) blockade: evidence and perspective. Pharmacol Res. 2006;53:440–5.

    Article  CAS  PubMed  Google Scholar 

  28. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–16.

    Article  CAS  PubMed  Google Scholar 

  29. Cross HR. Trimetazidine for stable angina pectoris. Expert Opin Pharmacother. 2001;2:857–75.

    Article  CAS  PubMed  Google Scholar 

  30. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using Trimetazidine and metoprolol: results of a randomized, double-blind, multicenter study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J. 2001;22:2267–74.

    Article  CAS  PubMed  Google Scholar 

  31. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev. 2005;19:CD003614.

    Google Scholar 

  32. Nitz RE, Fiedler VB. Molsidomine: alternative approaches to treat myocardial ischemia. Pharmacotherapy. 1987;7:28–37.

    CAS  PubMed  Google Scholar 

  33. Van Hove C, Carreer-Bruhwyler F, Géczy J, et al. Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina. Atherosclerosis. 2005;180:399–405.

    Article  PubMed  Google Scholar 

  34. Wagner F, Gohlke-Bärwolf C, Trenk D, et al. Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate (ISDN) during acute and short-term administration in stable angina pectoris. Eur Heart J. 1991;12:994–9.

    CAS  PubMed  Google Scholar 

  35. Messin R, Opolski G, Fenyvesi T, et al. Efficacy and safety of molsidomine once-a-day in patients with stable angina pectoris. Int J Cardiol. 2005;98:79–89.

    Article  PubMed  Google Scholar 

  36. Masumoto A, Mohri M, Shimokawa H, et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation. 2002;105:1545–7.

    Article  CAS  PubMed  Google Scholar 

  37. Vicari RM, Chaitman B, Keefe D, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol. 2005;46:1803–11.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Department, Rabin Medical Center, Petach Tikva, Sackler Faculty of Medicine, Tel Aviv University, 49100, Tel Aviv, Israel

    Danny Dvir & Alexander Battler

Authors
  1. Danny Dvir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Battler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Battler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dvir, D., Battler, A. Conventional and Novel Drug Therapeutics to Relief Myocardial Ischemia. Cardiovasc Drugs Ther 24, 319–323 (2010). https://doi.org/10.1007/s10557-010-6254-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-010-6254-8

Key words

Search

Navigation